Attached files

file filename
EX-99.1 - EXHIBIT 99.1 EARNINGS PR - Caladrius Biosciences, Inc.exhibit991earningspr.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
 
Date of Report (Date of earliest event reported): March 17, 2017


 CALADRIUS BIOSCIENCES, INC.
(Exact Name of Registrant as Specified in Charter)
 
 
Delaware
(State or Other Jurisdiction
of Incorporation)
001-33650
(Commission
File Number)
22-2343568
(IRS Employer
Identification No.)
 
 
106 Allen Road, 4th Floor, Basking Ridge, NJ 07920
(Address of Principal Executive Offices)(Zip Code)
 
(908) 842-0100
Registrant's Telephone Number
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
x

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
  






Item 2.02    Results of Operations and Financial Condition

The information in Item 8.01 is incorporated herein by reference.


Item 8.01    Other Events

On March 17, 2017, Caladrius Biosciences, Inc., a Delaware corporation (the “Company”) issued a press release in connection with its fiscal year ended December 31, 2016. A copy of the press release is filed as Exhibit 99.1 to this Current Report on From 8-K and is incorporated into this Item 8.01 by reference.


Item 9.01.     Financial Statement and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press Release, dated March 17, 2017






SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
CALADRIUS BIOSCIENCES, INC.
 
 
 
 
 
 
 
By:
/s/ David J. Mazzo
 
 
 
Name:
David J. Mazzo, PhD
 
 
Title:
Chief Executive Officer
 
Dated:    March 17, 2017